Imara-Logo-Color-RGB.jpg
Imara to Participate in Upcoming Investor Conferences
September 15, 2021 07:00 ET | Imara, Inc.
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present at Upcoming Investor Conferences
September 03, 2021 07:00 ET | Imara, Inc.
BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
August 06, 2021 07:00 ET | Imara, Inc.
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at...
Imara-Logo-Color-RGB.jpg
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
August 05, 2021 07:15 ET | Imara, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
July 30, 2021 07:00 ET | Imara, Inc.
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
June 17, 2021 07:00 ET | Imara, Inc.
BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 04, 2021 07:00 ET | Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara-Logo-Color-RGB.jpg
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 07:00 ET | Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Alliance Reg Med.png
New Report Demonstrates Potential for Cell and Gene Therapies to Provide Cost Savings
January 10, 2020 11:23 ET | Alliance for Regenerative Medicine
WASHINGTON, D.C., Jan. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene...
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $4.50
January 31, 2013 09:15 ET | Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Jan 31, 2013) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) ("ADVENTRX" or "ANX") with a twelve...